Papers by Thomas Wisniewski
bioRxiv (Cold Spring Harbor Laboratory), Apr 14, 2023
Bookmarks Related papers MentionsView impact
Journal of Alzheimer's Disease, Nov 12, 2009
Bookmarks Related papers MentionsView impact
Revue scientifique et technique, 2007
Prion diseases are a unique category of illness, affecting both animals and humans, where the und... more Prion diseases are a unique category of illness, affecting both animals and humans, where the underlying pathogenesis is related to a conformation change of the cellular form of a normal, self-protein called a prion protein (PrP(c) [C for cellular]) to a pathological and infectious conformation known as scrapie form (PrPsc [Sc for scrapie]). Currently, all prion diseases are without effective treatment and are universally fatal. The emergence of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease has highlighted the need to develop possible therapies. In Alzheimer's disease (AD), which has similarities to prion diseases, both passive and active immunisation have been shown to be highly effective at preventing disease and cognitive deficits in model animals. In a human trial of active vaccination in AD, despite indications of cognitive benefits in patients with an adequate humoral response, 6% of patients developed significant complications related to excessive...
Bookmarks Related papers MentionsView impact
Journal of Alzheimer's Disease, 2001
Bookmarks Related papers MentionsView impact
Journal of Neuropathology & Experimental Neurology, 2000
Bookmarks Related papers MentionsView impact
Journal of the American Chemical Society, Jan 7, 2015
Aggregation of amyloid β-peptide (Aβ) is implicated in the pathology of Alzheimer's disease (... more Aggregation of amyloid β-peptide (Aβ) is implicated in the pathology of Alzheimer's disease (AD), with the soluble, Aβ oligomeric species thought to be the critical pathological species. Identification and characterization of intermediate species formed during the aggregation process is crucial to the understanding of the mechanisms by which oligomeric species mediate neuronal toxicity and following disease progression. Probing these species proved to be extremely challenging, as evident by the lack of reliable sensors, due to their heterogeneous and transient nature. We describe here an oligomer-specific fluorescent chemical probe, BoDipy-Oligomer (BD-Oligo), developed through the use of the diversity-oriented fluorescent library approach (DOFLA) and high-content, imaging-based screening. This probe enables dynamic oligomer monitoring during fibrillogenesis in vitro and shows in vivo Aβ oligomers staining possibility in the AD mice model.
Bookmarks Related papers MentionsView impact
The Journal of Neuroscience, 2004
Immunization with amyloid-β (Aβ) 1-42 has been shown to reduce amyloid burden and improve cogniti... more Immunization with amyloid-β (Aβ) 1-42 has been shown to reduce amyloid burden and improve cognition in Alzheimer's disease (AD) model mice. In a human trial, possible cognitive benefit was found but in association with significant toxicity in a minority of patients. We proposed that immunization with nonfibrillogenic Aβ derivatives is much less likely to produce toxicity and have previously shown that one such derivative (K6Aβ1-30) can reduce amyloid burden in mice to a similar extent as Aβ1-42. Here, we immunized AD model mice (Tg2576) with Aβ1-30[E18E19] or with K6Aβ1-30[E18E19]. These peptides were designed to be nontoxic and to produce less T-cell response, which has been linked to toxicity. K6Aβ1-30[E18E19] induced primarily an IgM response, whereas Aβ1-30[E18E19] induced an IgG titer that was lower than previously seen with K6Aβ1-30 or Aβ1-42. However, both treated animal groups performed better than Tg controls in the radial arm maze. Amyloid burden was similar in Aβ1-30[...
Bookmarks Related papers MentionsView impact
The Journal of Neuroscience, 2009
The pathogenesis of Alzheimer's disease (AD) is thought to be related to the accumulation of ... more The pathogenesis of Alzheimer's disease (AD) is thought to be related to the accumulation of amyloid β (Aβ) in amyloid deposits and toxic oligomeric species. Immunomodulation is emerging as an effective means of shifting the equilibrium from Aβ accumulation to clearance; however, excessive cell mediated inflammation and cerebral microhemorrhages are two forms of toxicity which can occur with this approach. Vaccination studies have so far mainly targeted the adaptive immune system. In the present study, we have stimulated the innate immune system via the Toll-like receptor 9 (TLR9) with cytosine-guanosine-containing DNA oligodeoxynucleotides in Tg2576 AD model transgenic mice. This treatment produced a 66% and 80% reduction in the cortical (p= 0.0001) and vascular (p= 0.0039) amyloid burden, respectively, compared with nontreated AD mice. This was in association with significant reductions in Aβ42, Aβ40, and Aβ oligomer levels. We also show that treated Tg mice performed similarl...
Bookmarks Related papers MentionsView impact
Neurobiology of Aging, 2008
Bookmarks Related papers MentionsView impact
Journal of Virology, 2008
ABSTRACTPrion diseases such as scrapie involve the accumulation of disease-specific prion protein... more ABSTRACTPrion diseases such as scrapie involve the accumulation of disease-specific prion protein, PrPSc, in the brain. Toll-like receptors (TLRs) are a family of proteins that recognize microbial constituents and are central players in host innate immune responses. The TLR9 agonist unmethylated CpG DNA was shown to prolong the scrapie incubation period in mice, suggesting that innate immune activation interferes with prion disease progression. Thus, it was predicted that ablation of TLR signaling would result in accelerated pathogenesis. C3H/HeJ (Tlr4Lps-d) mice, which possess a mutation in the TLR4 intracellular domain preventing TLR4 signaling, and strain-matched wild-type control (C3H/HeOuJ) mice were infected intracerebrally or intraperitoneally with various doses of scrapie inoculum. Incubation periods were significantly shortened in C3H/HeJ compared with C3H/HeOuJ mice, regardless of the route of infection or dose administered. At the clinical phase of disease, brain PrPSclev...
Bookmarks Related papers MentionsView impact
Journal of Leukocyte Biology, 2007
Prion diseases are characterized by conversion of the cellular prion protein (PrPC) to a protease... more Prion diseases are characterized by conversion of the cellular prion protein (PrPC) to a protease-resistant conformer, the srapie form of PrP (PrPSc). Humoral immune responses to nondenatured forms of PrPSc have never been fully characterized. We investigated whether production of antibodies to PrPSc could occur in PrP null (Prnp−/−) mice and further, whether innate immune stimulation with the TLR9 agonist CpG oligodeoxynucleotide (ODN) 1826 could enhance this process. Whether such stimulation could raise anti-PrPSc antibody levels in wild-type (Prnp+/+) mice was also investigated. Prnp−/− and Prnp+/+ mice were immunized with nondenatured 139A scrapie-associated fibrils (SAF), with or without ODN 1826, and were tested for titers of PrP-specific antibodies. In Prnp−/− mice, inclusion of ODN 1826 in the immunization regime increased anti-PrP titers more than 13-fold after two immunizations and induced, among others, antibodies to an N-terminal epitope, which were only present in the i...
Bookmarks Related papers MentionsView impact
Expert Review of Vaccines, 2005
Bookmarks Related papers MentionsView impact
Biochemical Society Transactions, 2002
There is increasing recognition that numerous neurodegenerative conditions have the same underlyi... more There is increasing recognition that numerous neurodegenerative conditions have the same underlying pathogenetic mechanism, namely a change in protein conformation, where the β-sheet content is increased. In Alzheimer's disease, amyloid deposition in the form of neuritic plaques and congophilic angiopathy is driven by the conversion of normal soluble amyloid-β peptide (sAβ) to Aβ plaques; while in the prionoses the critical event is the conversion of normal prion protein, PrPc, to the disease-associated form, PrPsc. This common theme in the pathogenesis of these disorders and the extracellular localization of the accumulating abnormal protein make them highly amenable to therapeutic approaches based on experimental manipulation of protein conformation and clearance. A number of different approaches under current development include drugs which affect the processing of the precursor proteins drugs the clearance of the amyloidogenic protein, and which inhibit or prevent the confor...
Bookmarks Related papers MentionsView impact
American Journal of Psychiatry, 2012
Bookmarks Related papers MentionsView impact
The American Journal of Pathology, 2001
Bookmarks Related papers MentionsView impact
The American Journal of Pathology, 2002
Bookmarks Related papers MentionsView impact
The American Journal of Pathology, 2004
Bookmarks Related papers MentionsView impact
Acta Neuropathologica, 2007
Bookmarks Related papers MentionsView impact
Annals of neurology, Jan 2, 2018
Bookmarks Related papers MentionsView impact
Acta neuropathologica, Jan 17, 2015
Bookmarks Related papers MentionsView impact
Uploads
Papers by Thomas Wisniewski